Novo Integrated Sciences, Inc. (NASDAQ: NVOS) (the “Company” or “Novo”), has announced that Dr. Joseph Chalil, MD, MBA, FACHE, Novo’s Chief Medical Officer, will represent Novo and Acenzia as a member of the Team Canada Trade Mission to India slated for October 2023, led by the Honorable Mary Ng, Canada’s Minister of International Trade, Export Promotion, Small Business and Economic Development.
Dr. Chalil, the Publisher of The Universal News network (www.theunn.com) will repersent Acenzia, a nutraceutical manufacturer and a Canadian subsidiary of Novo, at the Trade Mission to India.
For Acenzia, being selected to be a member of this Canada-India Trade Mission is an honor and validates Acenzia’s dedication to introducing its high-quality evidenced-based dietary, nutraceutical, and food products to a rapidly growing consumer base.
The Canada-India Trade Mission, scheduled to visit Mumbai, Bangalore, and Hyderabad, India from October 8-14, 2023, is an important component of Canada’s Indo-Pacific strategy to deepen bilateral trade and to further expand the economic partnership between Canada and India, while also recognizing the critical importance of the Indo-Pacific region for Canada’s prosperity.
The Indo-Pacific region encompasses 40 economies, over 4 billion people, and $47.19 trillion in economic activity, and it represents over one-third of all global economic activity. As India and the Indo-Pacific burgeoning middle class expands, so does the demand for access to high-quality healthcare related services, devices, information, and products.
Robert Mattacchione, Novo’s CEO and Chairman of the Board, stated, “It is both an honor and significant opportunity for our company to have been selected to participate as an invited member of the Team Canada Trade Mission to India. We are excited to showcase the potential of our company and begin the process of nurturing the opportunities and the relationships this initiative will bring to light.”
Acenzia’s 36,000 square foot facility is located in Windsor Ontario Canada and includes Class 100 pharmaceutical grade cleanrooms and certified laboratories from which Acenzia creates and manufactures evidenced-based dietary, nutraceutical, and food products that can be validated through personalized diagnostics. Acenzia is dedicated to the creation of innovative therapeutics and diagnostics that enables individualized health optimization.
Dr. Chalil is an author and the Chief Strategy Officer of the American Association of Physicians of Indian Origin. He is also the Chief Medical Officer of Novo Integrated Sciences, a Nasdaq-listed company that runs hundreds of clinics in North America. He is also the President of Clinical Consultants International. He serves as the chairman of the health system advisory board, a professor at the college of business, and a member of the NSU MD executive leadership council at Nova Southeastern University in Florida.
His book, “Beyond the Covid-19 pandemic: Envisioning a Better World by Transforming the Future of Healthcare, was an Amazon Best Seller. In addition, he is the author of several scientific and research papers in international publications and the publisher of “The Universal News Network.”
Acenzia, founded in 2015, is licensed by multiple international government agencies including Health Canada, the U.S. FDA, and the European Union for Good Manufacturing Practices (GMP) for over-the-counter and dietary supplement manufacturing. In addition, Acenzia maintains multiple third-party licenses including from the National Sanitation Foundation International (NSF) for meeting the required public health standards for manufacturing food, nutrition, and supplements. For more information, please visit www.acenzia.com
Novo Integrated Sciences, Inc. is pioneering a holistic approach to patient-first health and wellness through a multidisciplinary healthcare ecosystem of services and product innovation. Novo offers an essential and differentiated solution to deliver, or intend to deliver, these services and products through the integration of medical technology, advanced therapeutics, and rehabilitative science.
The Company’s decentralized healthcare business model is centered on three primary pillars to best support the transformation of non-catastrophic healthcare delivery to patients and consumers:
- First Pillar: Service Networks. Deliver multidisciplinary primary care services through (i) an affiliate network of clinic facilities, (ii) small and micro footprint sized clinic facilities primarily located within the footprint of box-store commercial enterprises, (iii) clinic facilities operated through a franchise relationship with the Company, and (iv) corporate operated clinic facilities.
- Second Pillar: Technology. Develop, deploy, and integrate sophisticated interconnected technology, interfacing the patient to the healthcare practitioner thus expanding the reach and availability of the Company’s services, beyond the traditional clinic location, to geographic areas not readily providing advanced, peripheral based healthcare services, including the patient’s home.
- Third Pillar: Products. Develop and distribute effective, personalized health and wellness product solutions allowing for the customization of patient preventative care remedies and ultimately a healthier population. The Company’s science-first approach to product innovation further emphasizes our mandate to create and provide over-the-counter preventative and maintenance care solutions.
Innovation through science combined with the integration of sophisticated, secure technology assures Novo Integrated Sciences of continued cutting-edge advancement in patient-first platforms.
For more information concerning Novo Integrated Sciences, please visit www.novointegrated.com.
